Neovacs S.A.
PAR: ALNEV.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hugo Brugiere
- Employees
- 22
- Headquarters
- Paris, France
- IPO year
- 2010
- Market cap
- €95.0
- Website
- https://www.neovacs.com
Loading ALNEV…
Loading profile data…Frequently asked questions about ALNEV
What does Neovacs S.A. (ALNEV.PA) do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an a...
Where does ALNEV.PA trade?
Neovacs S.A. (ALNEV.PA) trades on the Euronext Paris.
What sector is ALNEV.PA in?
Neovacs S.A. (ALNEV.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Neovacs S.A.?
Hugo Brugiere is the chief executive officer of Neovacs S.A. (ALNEV.PA).
Where is Neovacs S.A. headquartered?
Neovacs S.A. is headquartered in France.
Does ALNEV.PA pay a dividend?
Neovacs S.A. (ALNEV.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALNEV.PA go public?
Neovacs S.A. (ALNEV.PA) completed its initial public offering in 2010.